Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/20 | $25,000,000 | Series A |
VenBio | undisclosed |
